Advancing Antibiotic Use and Preventing Hearing Loss in Babies: Evidence-generation plan for Genedrive MT-RNR1 ID Kit

By Staff Writer

August 14, 2023

NICE has recommended further evidence generation for the Genedrive MT-RNR1 ID Kit, a technology developed to detect a genetic variant that guides antibiotic use and prevents hearing loss in babies.

This plan outlines the gaps in evidence for the technology and the real-world data that needs to be collected for a future NICE review. The responsibility for data collection and analysis lies with the technology developer.

Support for evidence generation will be facilitated by the Office for Life Sciences, pending business case approval. This includes funding for evidence generation consortia, bringing together analytical partners, implementation sites, and developers.

Guidance on commissioning and procurement of the technology will be provided by NHS England, who is also developing a digital health technology policy framework.

After 3 years of evidence generation, the developer should submit the evidence to NICE for review and decision making on routine adoption in the NHS.

Reference url

Recent Posts

value-based drug pricing
      

Optimizing Value-Based Drug Pricing in Japan with MARIE Framework

🔍 Are we pricing drugs based on true value?

The introduction of the MARIE framework in Japan revolutionizes value-based drug pricing by considering not just costs, but the actual benefits drugs provide to patients and society. This innovative approach significantly adjusts prices based on updated clinical data and allows for more equitable access to therapies.

Curious about how MARIE can reshape drug pricing and pharmaceutical innovation? Dive into the full article for insights!

#SyenzaNews #HealthEconomics #MarketAccess

modifiable risk factors
        

Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?

A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.

Dive into the article to explore how these findings could shape future healthcare models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #DigitalTransformation

drug price regulation
      

Navigating Drug Price Regulation: Evaluating the Executive Order’s Potential Impacts and Challenges

💊 Curious about the future of drug pricing in the U.S.?

The recent executive order aims to tackle escalating prescription drug costs through measures like international reference pricing and enhanced transparency. However, the implications of these policies could be more complex than anticipated, with potential risks to market access and innovation.

Dive into the article for a detailed analysis of how these regulations could shape the pharmaceutical landscape and what it means for healthcare access in the U.S.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.